With complex biologics such as monoclonal antibodies (mAb), antibody-drug conjugates (ADCs) and cell and gene therapies (CGTs) attracting the attention of global big pharma companies, the scope of precision medicine has grown in recent years.
While these therapies hold great potential for patients and commercial revenues, they are often complex to produce at scale, which can complicate their road to market and subsequent uptake.
Traditionally, drug manufacturers have relied on Chinese hamster ovary (CHO) cells to produce large molecules. CHO cell lines were explored for manufacturing biologi